Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YL211 in Advanced Solid Tumors
NCT06384352Phase 1Recruiting
- Sponsor
- MediLink Therapeutics
- Start
- May 2024
- Primary completion
- Jun 2031
- Modality
- Small Molecules, Antibody-Drug Conjugates (ADCs)
- Countries
- 4
01
Overview
Phase 1, randomised, open-label trial of YL211 in solid tumor, non-small cell lung cancer (NSCLC) and colorectal cancer (CRC) (6 arms), sponsored by MediLink Therapeutics. Primary endpoints: Adverse Events at 36 months, Dose-Limiting Toxicities at 36 months and 2 more. Started May 2024; status: recruiting.
02
Drugs
YL211
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT06384352.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06384352.